CytoDyn to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Rhea-AI Summary

CytoDyn (OTCQB: CYDY), a clinical-stage biotech company developing leronlimab, will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025. The company's CFO, Robert E. Hoffman, will present on September 10 at 1:30 p.m. EDT at the Lotte New York Palace Hotel.

Leronlimab, the company's lead candidate, is a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with potential applications across multiple indications. The presentation will be available via webcast, and management will be available for one-on-one meetings with conference attendees.

VANCOUVER, Washington, Aug. 28, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage biotechnology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, today announced that management will participate in the H.C. Wainwright 27^th Annual Global Investment Conference being held September 8 to 10, 2025, at the Lotte New York Palace Hotel in New York City.

Robert E. Hoffman, Chief Financial Officer, will deliver a presentation on Wednesday, September 10, at 1:30 p.m. EDT, which will be accessible via webcast here, and will be available for one-on-one meetings with registered conference attendees.

About CytoDyn

CytoDyn is a clinical-stage biotechnology company dedicated to advancing leronlimab, a first-in-class humanized monoclonal antibody that targets the CCR5 receptor, a key regulator of immune function implicated in cancer, infectious diseases, and autoimmune disorders.

Guided by a mission to improve patients’ quality of life through therapeutic innovation, CytoDyn is committed to integrity, responsibility, and service as it works to bring transformative treatments to patients worldwide.

For more information, please visit www.cytodyn.com and follow us on LinkedIn.

Investor Relations

CytoDyn Inc.
ir@cytodyn.com

Media Contacts

Rob Haney, Ph.D., or Ignacio Guerrero-Ros, Ph.D.
Russo Partners, LLC
CytoDyn@russopartnersllc.com

FAQ

When is CytoDyn presenting at the H.C. Wainwright Conference 2025?

CytoDyn's CFO Robert E. Hoffman will present on Wednesday, September 10, 2025, at 1:30 p.m. EDT at the Lotte New York Palace Hotel in New York City.

What is CytoDyn's main drug candidate leronlimab?

Leronlimab is a first-in-class humanized monoclonal antibody that targets the CCR5 receptor and has therapeutic potential across multiple indications.

Who will represent CYDY at the H.C. Wainwright Conference?

Robert E. Hoffman, CytoDyn's Chief Financial Officer, will deliver the presentation and be available for one-on-one meetings with conference attendees.

How can investors access CytoDyn's H.C. Wainwright conference presentation?

The presentation will be accessible via webcast through a provided link, allowing remote viewing of the company's presentation.